β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension

Neurobiology of Aging

Volumn 30, Issue 2, 2009, Pages 222-228

  Gentile, Maria Teresa ^a   Poulet, Roberta ^a   Pardo, Alba Di ^a   Cifelli, Giuseppe ^a   Maffei, Angelo ^a   Vecchione, Carmine ^a   Passarelli, Francesca ^b   Landolfi, Alessandro ^a   Carullo, Pierluigi ^a   Lembo, Giuseppe ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Amyloid; Blood brain barrier; Brain; Hypertension; Immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA COARCTATION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART HEMODYNAMICS; HIPPOCAMPUS; HYPERTENSION; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RISK FACTOR;

AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 57749116386     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.06.005     Document Type: Article

References (36)

1. Batia R., Lin H., and Lal R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for Abeta P channel mediated cellular toxicity. FASEB J. 14 (2000) 1233-1243
2. Bennett S.A., Pappas B.A., Stevens W.D., Davidson C.M., Fortin T., and Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol. Aging 21 2 (2000) 207-214
3. Buèe L., Hof P.R., and Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann. N.Y. Acad. Sci. 826 (1997) 7-24
4. Claudio L. Ultrastructural features of the blood brain barrier in biopsy tissue from Alzheimer disease patients. Acta Neuropathol. 91 (1996) 6-14
5. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4 2 (2007) 147-152
6. Das P., Howard V., Loosbrock N., Dickson D., Murphy M.P., and Glode T.E. Amyloid β immunization effectively reduces amyloid depositino in FcRγ -/- knock out mice. J. Neurosci. 23 (2003) 8532-8538
7. de la Torre J.C. Alzheimer disease as a vascular disorder. Stroke 33 (2002) 1152-1162
8. de la Torre J.C. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer pathogenesis. Neurobiol. Aging 21 (2000) 331-342
9. De Simoni M.G., Rossi E., Storini C., Pizzimenti S., Echart C., and Bergamaschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am. J. Pathol. 164 (2004) 1857-1863
10. Deane R., Wu Z., and Zlokovic B.V. RAGE (Yin) versus LRP (Yan) Balance regulates Alzheimer amyoid β peptide clearance through transport across the blood brain barrier. Stroke 35 (2004) 2628-2631
11. Dodart J.C., Bales K.R., Gannon K.S., Green S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer disease model. Nat. Neurosci. 5 (2002) 452-457
12. Farkas E., De Vos R.A.I., Janse Steur E.N.H., and Luiten P.G.M. Are Alzheimer's disease, hypertension and cerebrocapillary damage related?. Neurobiol. Aging 21 (2000) 235-243
13. Gasparini L., Racchi M., Binetti G., Trabucchi M., Solerte S.B., Alkon D., Etcheberrigaray R., Gibson G., Blass J., Paoletti R., and Govoni S. Peripheral markers in testing pathophisiological hypotheses and diagnosing Alzheimer's disaese. FASEB J. 12 (1998) 17-35
14. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 100 18 (2003) 10417-10422
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disaese: progress and problems on teh road to therapeutics. Science 297 (2002) 353-356
16. Hofman A., Ott A., and Breteler M.M.B. Atherosclerosis, apolipoprotein e, and prevalence of dementia and Alzheimer disease in the Rotterdam Study. Lancet 349 (1997) 151-154
17. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
18. Iwata N., Higuchi M., and Saido T.C. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 108 2 (2005) 129-148
19. Kisilewsky R. Amyloid beta theads in the fabric of Alzheimer's disease. Nat. Med. 4 (1998) 772-773
20. Lemere C.A., Spooner E.T., La Francois J., Malester B., Mori C., Leverone J.F., matsuoka Y., Taylor J.W., DeMattos R.B., Holtzman D.M., Clements J.D., Selkoe D.J., and Duff K.E. Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. 14 (2003) 10-18
21. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 7082 (2006) 352-357
22. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., and Golde T.E. Anti- Aβ42 and anti-Aβ40 specific mAbs attenuate amyolid depositino in an Alzheimer disease mouse model. J. Clin. Invest. 116 (2006) 193-201
23. Matter K., and Baslda M.S. Holey barrier: claudins and the regulation of brain endothelial permeability. J. Cell Biol. 161 (2003) 459-460
24. Mayhan W.G. Regulatrion of blood brain barrier permeability. Microcirculation 8 (2001) 89-104
25. Poulet R., Gentile M.T., Vecchione C., Distaso M., Aretini A., Fratta L., Russo G., Echart C., Maffei A., De Simoni M.G., and Lembo G. Acute hypertension induces oxidative stress in brain tissues. J. Cereb. Blood Flow Metab. 26 (2006) 253-262
26. Qiu W.Q., and Folstein M.F. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging. 27 2 (2006) 190-198
27. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 (2001) 177-180
28. Skoog I., and Gustafson D. Update on hypertension and Alzheimer's disease. Neurol. Res. 28 6 (2006) 605-611
29. Skoog I., Lernfeldt B., and Landhal S. Year longituidinal study of blood pressure and dementia. Lancet 347 (1996) 1141-1145
30. Stamatovic S.M., Shakui P., Keep R.F., Moore B.B., Kunkel S.L., Van Rooijen N., and Andjelkovic A.V. Monocyte chemoattractant protein-1 regulation of blood brain barrier permeability. J. Cereb. Blood Flow Metab. 25 (2005) 593-606
31. Stewart R. Cardiovascular factors in Alzheimer dissease. J. Neurol. Neurosurg. Psychiatry 65 (1998) 143
32. Walsh D.M., Klyubin I., Fadeeva J.C., Koolen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 4 (2002) 535-539
33. Wilcock D.M., Rojiani A., and Rosenthal A. Passive amyloid immunotherapy clears amyloid nd transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24 (2004) 6144-6151
34. Zhu Y.J., Lin H., and Lal R. Fresh and non fibrillar amyloid beta protein (1-40) induces rapid cellular degeneration in aged human fibroblasts: evidences for AbetaP-channel mediated cellular toxicity. FASEB J. 14 (2000) 1244-1254
35. Zlokovic B. Clearing beta amyloid through the blood brain barrier. J. Neurosci. 89 (2004) 807-811
36. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., and Frangione B. Clearance of amyoid β peptide from brain: transport or metabolism?. Nat. Med. 6 (2000) 718-719